Exact Sciences shareholders approve merger with Abbott Laboratories
Exact Sciences Corp. shareholders have approved the proposed merger with Abbott Laboratories, making Exact Sciences a wholly-owned subsidiary of Abbott. The merger agreement passed with significant shareholder support, although the advisory vote on executive compensation was not approved. The completion of the merger is pending regulatory approvals and other customary closing conditions.
Exact Sciences Stockholders Approve Acquisition by Abbott
Exact Sciences Corporation stockholders have approved the proposed acquisition by Abbott, with over 99% of votes cast in favor of the transaction. The acquisition is expected to close before the end of the second calendar quarter of 2026, granting Exact Sciences stockholders $105.00 in cash per share. Exact Sciences is a leading provider of cancer screening and diagnostic tests, including Cologuard® and Oncotype DX®.
Exact Sciences Corp.: The Quiet Cancer-Test Stock Everyone’s Watching
Exact Sciences Corp., known for its Cologuard at-home colon cancer test, is gaining significant attention due to new data, analyst calls, and increased momentum in cancer testing. The company is exploring blood-based cancer tests and oncology genomics, positioning itself as a key player in early cancer detection in the US. While offering substantial benefits like at-home convenience and broad insurance coverage, the company also faces challenges including competition, high R&D costs, and stock volatility.
Exact Sciences Corp.: The Quiet Cancer-Test Stock Everyone’s Watching
Exact Sciences Corp., known for its Cologuard at-home colon cancer test, is gaining significant attention due to new data, analyst calls, and momentum in cancer diagnostics. The US-focused company is expanding its portfolio into blood-based cancer tests and oncology genomics, aiming to make early detection more accessible. While offering substantial benefits for patients and long-term growth potential for investors, the stock faces volatility from competition, R&D costs, and reimbursement pressures.
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up
Exact Sciences (EXAS) reported a net loss of 21 cents per share in Q4 2025, matching estimates, with revenues of $878.4 million beating the Zacks Consensus Estimate. Consolidated revenues for the full year reached $3.25 billion, an increase of 17.7%. The company saw strong revenue growth in both its Screening and Precision Oncology segments, though increased operating expenses led to a higher operating loss compared to the previous year.
Aberdeen Group plc Increases Stock Position in Exact Sciences Corporation $EXAS
Aberdeen Group plc significantly increased its stake in Exact Sciences Corporation (NASDAQ:EXAS) by 52.7% in the third quarter, bringing its total holdings to 304,609 shares valued at approximately $16.7 million. Despite this increase in institutional investment, Exact Sciences missed its quarterly EPS consensus, reporting ($0.21) against an expected $0.08, though revenue beat estimates at $878.4 million with 23.1% year-over-year growth. The company currently holds an average analyst rating of "Hold" with a consensus price target of $89.56.
Exact Sciences Faces Rising Operational Risk and Strategic Constraints Amid Pending Abbott Merger
Exact Sciences Corp (EXAS) is facing increased operational and strategic risks due to its pending merger with Abbott. The uncertainty surrounding the transaction could impact its ability to attract and retain personnel, and affect relationships with customers and suppliers, potentially leading to reduced revenue and a negative effect on its stock. Additionally, the merger agreement restricts Exact Sciences' strategic and operational flexibility, limiting its response to market changes and growth initiatives, which could impair its competitive position and financial health.
Illinois Municipal Retirement Fund Boosts Stake in Exact Sciences Corporation $EXAS
The Illinois Municipal Retirement Fund increased its stake in Exact Sciences Corporation by 20.1% in Q3, now holding 97,134 shares valued at approximately $5.31 million. This move is part of a broader trend of institutional buying, despite the company's recent earnings miss and a consensus "Hold" rating from analysts with an average price target of $89.56. Exact Sciences currently trades near its 52-week high, exhibiting significant revenue growth alongside a negative net margin.
Exact Sciences: Fourth Quarter Earnings Overview
Exact Sciences Corp. reported a net loss of $86 million in the fourth quarter, or $0.45 per share, with an adjusted loss of $0.21 per share, falling short of Wall Street expectations. Despite the loss, the company generated $878.4 million in quarterly revenue, surpassing analyst forecasts. For the full year, Exact Sciences recorded a total loss of $207.9 million and revenues of $3.25 billion.
Exact Sciences: Q4 Earnings Snapshot
Exact Sciences Corp. reported a Q4 net loss of $86 million, or 45 cents per share, though adjusted losses were 21 cents per share, missing Wall Street expectations. The company's revenue of $589.3 million for the quarter, however, beat Street forecasts. For the full year, Exact Sciences reported a loss of $209.7 million on revenue of $3.02 billion.
EXACT SCIENCES CORP SEC 10-K Report
Exact Sciences Corp (EXAS) has released its 2025 10-K report, highlighting significant financial and operational growth, with revenue exceeding $3.2 billion driven by Cologuard and Oncotype DX tests. The company reported a reduced net loss, new product launches like Cologuard Plus and Cancerguard, and expanded laboratory capacity. Key strategies include continued product adoption, international expansion, and a multi-year productivity plan to achieve $150 million in annual savings, alongside a pending merger with Abbott Laboratories to enhance market positioning.
Exact Sciences: Q4 Earnings Snapshot
Exact Sciences Corp. reported a Q4 loss of $86 million, or 45 cents per share, missing Wall Street's breakeven expectations. Adjusted losses were 21 cents per share. However, the molecular diagnostics company surpassed revenue forecasts with $878.4 million for the quarter, contributing to a full-year loss of $207.9 million on $3.25 billion in revenue.
Exact Sciences Corp. Reports Record Fourth Quarter and Full Year 2025 Results
Exact Sciences Corp. announced record financial results for the fourth quarter and full year 2025, with total revenue reaching $3.25 billion for the year, an 18% increase. Despite a net loss for the year, the company saw significant growth in its Screening and Precision Oncology segments and launched three new tests. A merger with Abbott Laboratories is anticipated to close in Q2 2026, further expanding its market position.
Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results
Exact Sciences Corp. announced record fourth-quarter and full-year 2025 results, with total revenue reaching $878 million for Q4 and $3.25 billion for the full year. The company highlighted significant advancements in its cancer screening and diagnostic tests, including clinical study results for its Oncodetect® molecular residual disease test in breast cancer and pivotal validation results for the Oncoguard® Liver blood test. Exact Sciences also noted its pending merger with Abbott Laboratories, expected to close in Q2 2026.
Exact Sciences: Q4 Earnings Snapshot
Exact Sciences Corp. reported a Q4 loss of $86 million, or 45 cents per share, missing Wall Street expectations for breakeven earnings. Despite the loss, the molecular diagnostics company recorded revenues of $878.4 million, surpassing analyst forecasts. For the full year, Exact Sciences posted a loss of $207.9 million on revenues of $3.25 billion.
Exact Sciences: Q4 Earnings Snapshot
Exact Sciences Corp. reported a Q4 loss of $86 million, or 45 cents per share, which fell short of Wall Street expectations when adjusted for non-recurring costs. The company's revenue for the quarter was $878.4 million, beating Street forecasts. For the full year, Exact Sciences recorded a loss of $207.9 million on revenue of $3.25 billion.
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) reported a Q4 loss of $0.21 per share, missing the Zacks Consensus Estimate of breakeven, but surpassed revenue estimates with $878.38 million. The company has a Zacks Rank #3 (Hold) and its shares have seen a 1.6% increase year-to-date, outperforming the S&P 500. Investors are now looking to management commentary and future earnings estimates for the stock's direction.
Exact Sciences: Fourth Quarter Earnings Overview
Exact Sciences reported a net loss of $86 million, or $0.45 per share, in the fourth quarter, with an adjusted loss of $0.21 per share, missing Wall Street expectations for a break-even performance. Despite this, the company's revenue reached $878.4 million, exceeding analyst forecasts. For the full year, Exact Sciences recorded a total loss of $207.9 million on revenues of $3.25 billion.
Exact Sciences Corporation (NASDAQ:EXAS) Given Consensus Rating of "Hold" by Brokerages
Twenty-four brokerages have issued a consensus "Hold" rating for Exact Sciences Corporation (NASDAQ:EXAS), with an average 12-month target price of $89.56. This comes after several firms downgraded the stock from "buy" to "hold" despite some increasing their price targets. Insider transactions also show EVP Jacob A. Orville selling 5,000 shares, reducing his holdings by 17.7%, while institutional ownership remains high at 88.82%.
Allianz Asset Management GmbH Makes New Investment in Exact Sciences Corporation $EXAS
Allianz Asset Management GmbH recently acquired a new stake of 93,776 shares in Exact Sciences (NASDAQ:EXAS), valued at approximately $5.13 million. Despite this new investment, several research firms have downgraded EXAS to a "Hold" rating, with an average price target below the current trading price. Insider selling has also been noted, with EVP Jacob A. Orville selling 5,000 shares.
Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings?
Despite a 152% stock price increase in the last six months, experts are advising caution on Exact Sciences (EXAS) due to concerns about its historical cash burn and negative return on invested capital. The company's average free cash flow margin has been negative 2% over five years, and its five-year average ROIC was negative 13.7%, indicating it has lost money on growth initiatives. Analysts believe the stock's current valuation at 121.8x forward P/E has priced in too much good news, suggesting better investment opportunities exist elsewhere.
PTAB Tosses 2nd Patent On Cologuard Colon Cancer Test
The Patent Trial and Appeal Board (PTAB) has invalidated a second patent related to Exact Sciences' Cologuard colon cancer test, based on arguments from Geneoscopy. The PTAB found all challenged claims in the patent obvious, following a similar invalidation of claims in another Cologuard patent months prior.
Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences’ ’746 Patent
Geneoscopy, Inc. announced that the Patent Trial and Appeal Board (PTAB) has invalidated all 10 challenged claims of Exact Sciences’ U.S. Patent No. 11,970,746, following a previous invalidation of another of Exact Sciences' patents. This decision removes all patent claims asserted by Exact Sciences against ColoSense, Geneoscopy's noninvasive colorectal cancer screening test, clearing the path for its continued commercialization. Geneoscopy has also filed counterclaims against Exact Sciences for issues including breach of contract and false advertising.
Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences’ ’746 Patent
Geneoscopy has won its second Patent Trial and Appeal Board (PTAB) decision, invalidating all challenged claims of Exact Sciences’ U.S. Patent No. 11,970,746. This ruling, coupled with a previous decision invalidating another Exact Sciences patent, removes all patent hurdles asserted against Geneoscopy's colorectal cancer screening test, ColoSense. Geneoscopy views this as a critical step toward ensuring patient access to innovative screening options and protecting patient choice.
Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences’ ’746 Patent
Geneoscopy has won a second Patent Trial and Appeal Board (PTAB) decision, invalidating all challenged claims of Exact Sciences’ U.S. Patent No. 11,970,746. This follows an earlier decision invalidating claims of another Exact Sciences' patent, effectively removing all patent hurdles for Geneoscopy's ColoSense colorectal cancer screening test in the ongoing litigation. Geneoscopy's CEO emphasized that this outcome ensures patient access to crucial screening options and protects innovation in noninvasive screening solutions.
The Truth About Exact Sciences Corp: Is This Cancer-Test Stock Quietly Going Viral or About to Flop?
This article examines Exact Sciences Corp (EXAS), a company specializing in cancer screening and diagnostic tests, to determine if it's a promising investment or a potential trap for investors. It discusses the company's focus on early cancer detection, its position in the biotech and lab testing sectors, and its stock's volatility. The article also compares Exact Sciences to its competitors and offers a verdict on whether the stock is a "cop" or a "drop" for different types of investors.
The Truth About Exact Sciences Corp: Is This Cancer-Test Stock Quietly Going Viral or About to Flop?
This article examines Exact Sciences Corp (EXAS), a biotechnology company focused on cancer screening and diagnostic tests, to determine if it's a promising investment or a potential trap. It highlights the company's mission in early cancer detection, its reliance on biotech and data-driven technology, and its position in a competitive market. The author concludes that EXAS is a high-risk, long-term play for investors comfortable with volatility, emphasizing its innovative approach to healthcare despite not being a "safe" stock.
Principal Financial Group Inc. Grows Position in Exact Sciences Corporation $EXAS
Principal Financial Group Inc. increased its stake in Exact Sciences Corporation by 14.3% in the third quarter of 2025, now owning 844,648 shares valued at $46.21 million. Analysts have a consensus "Hold" rating on Exact Sciences with an average price target of $89.56, despite several firms recently raising targets to $105. The company beat Q3 earnings estimates but remains unprofitable, trading near its one-year high.
Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests
Exact Sciences celebrates the passage of federal legislation creating a Medicare coverage pathway for multi-cancer early detection (MCED) tests. This legislation addresses the lack of recommended screenings for nearly 70% of annual cancer cases and deaths, offering expanded access to emerging technology for Medicare beneficiaries following FDA approval. The company highlights its Cancerguard® test as a potential tool to detect various cancers early, complementing existing screenings and potentially reducing late-stage diagnoses.
Exact Sciences welcomes Medicare coverage pathway for multi-cancer tests
Exact Sciences announced that federal legislation, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, has passed, establishing a Medicare coverage pathway for multi-cancer early detection tests. This legislation creates a framework for future coverage of MCED tests following FDA approval and CMS implementation. Exact Sciences praised the bipartisan support and highlighted the potential of its Cancerguard test to detect multiple cancers, aiming to reduce stage IV diagnoses by 45% when combined with standard screenings.
Exact Sciences stock hits 52-week high at $102.69
Exact Sciences Corporation's stock reached a new 52-week high of $102.69, reflecting an 87.49% increase over the past year and a 114.61% surge in six months, based on strong investor confidence and strategic advancements. This milestone comes amidst news of Abbott Laboratories' plan to acquire Exact Sciences for approximately $21 billion, leading to analyst downgrades to "Neutral" or "Hold" and a $105 price target. The company has also made financial adjustments for executive bonuses and equity awards in anticipation of the merger.
Breast cancer test spares 1.6M from chemo, averages $10K lifetime savings
Exact Sciences' Oncotype DX Breast Recurrence Score® test has surpassed two million patients worldwide, becoming a global standard for guiding personalized breast cancer treatment. The test has helped an estimated 1.6 million patients safely avoid unnecessary chemotherapy and has resulted in approximately $10,000 in average lifetime savings per patient in the U.S. healthcare system. It is the only genomic test proven to predict adjuvant chemotherapy benefit for early-stage HR+, HER2- breast cancer patients.
Multiple Tailwinds Lifted Exact Sciences Corporation (EXAS) in 2025
Baron Discovery Fund's Q4 2025 investor letter highlighted Exact Sciences Corporation (EXAS) as a significant contributor to its performance, citing the company's focus on early colorectal cancer detection with its Cologuard test. The fund noted EXAS shares outperformed in 2025 due to commercial team restructuring and the announcement of Abbott Laboratories' $23 billion acquisition. Despite its success, the fund suggests some AI stocks might offer greater return potential.
EFG Asset Management North America Corp. Purchases 12,900 Shares of Exact Sciences Corporation $EXAS
EFG Asset Management North America Corp. increased its stake in Exact Sciences Corporation (NASDAQ:EXAS) by 19.6% in the third quarter, acquiring an additional 12,900 shares to bring its total holdings to 78,675 shares valued at approximately $4.305 million. This coincides with Exact Sciences reporting strong Q3 results, beating EPS and revenue expectations, despite analysts projecting negative full-year EPS. The article also notes significant insider selling, with company insiders owning about 1.2% of the stock, while institutional investors hold nearly 88.8%.
Exact Sciences Corp. (EXAS) Rose Following the Acquisition Announcement
Exact Sciences Corp. (EXAS) saw its stock rise after Abbott announced plans to acquire the cancer diagnostics company at a significant premium. The Meridian Growth Fund, managed by ArrowMark Partners, highlighted EXAS as a leading contributor in its Q4 2025 investor letter, noting renewed growth and the introduction of a new test. Despite this, Exact Sciences is not among the 30 most popular stocks among hedge funds, with some believing AI stocks offer greater upside.
Lobbying Update: $420,000 of EXACT SCIENCES lobbying was just disclosed
EXACT SCIENCES (EXAS) has disclosed $420,000 in lobbying expenditures for Q4 2025, focusing on legislation supporting cancer screening and patient access to diagnostics. The article also details recent insider sales of EXAS stock, significant movements by institutional investors, and current analyst ratings with price targets for the company.
Halper Sadeh Investigates Potential Securities Violations by Penumbra, Exact Sciences, DigitalBridge, and Flushing Financial
Halper Sadeh is investigating potential securities violations concerning the acquisitions of Penumbra, Exact Sciences, DigitalBridge, and Flushing Financial. The firm is examining whether the proposed terms for these acquisitions adequately protect shareholder rights and potentially seeking increased compensation or disclosures for investors. The article details the specific acquisition terms for each company and includes analyst views and price targets for DigitalBridge (DBRG).
Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Playbook on Early Cancer Detecti
Exact Sciences Corp. is transforming cancer detection through molecular diagnostics, notably with Cologuard for colorectal cancer screening and Oncotype DX for guiding breast cancer treatment. The company aims to provide a comprehensive platform covering risk detection, therapy selection, and recurrence monitoring, leveraging scientific rigor and a "product ecosystem" approach over traditional lab tests. This strategy gives Exact Sciences a competitive edge by creating clinically trusted, reimbursable, and widely adopted tools, ensuring its growth hinges on expanding its molecular oncology testing capabilities despite market volatility and competition.
Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Playbook on Early Cancer Detecti
Exact Sciences Corp. is transforming cancer detection through its platform, anchored by Cologuard for colorectal cancer screening and Oncotype DX for treatment guidance. The company focuses on making molecular diagnostics routine and accessible, aiming to cover the full lifecycle of cancer testing from risk detection to recurrence monitoring. By leveraging software-inspired thinking, data science, and strategic partnerships, Exact Sciences is positioning itself as a leader in precision oncology, despite competition from rivals like Guardant Health and GRAIL.
Exact Sciences Corporation $EXAS Shares Sold by EULAV Asset Management
EULAV Asset Management reduced its stake in Exact Sciences Corporation by 6% in the third quarter, selling 17,000 shares but still holding 266,000 shares valued at approximately $14.55 million. Meanwhile, company insiders Brian Baranick and Jacob A. Orville also sold shares, decreasing their holdings. Analysts have a mixed view on Exact Sciences, with a consensus "Hold" rating, despite the company recently beating quarterly earnings and revenue estimates.
Exact Sciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Exact Sciences Corporation (EXAS) to Abbott Laboratories (ABT) for $105.00 cash per share. KSF aims to determine if this offer adequately values Exact Sciences and if the sales process was fair to shareholders. Shareholders who believe the offer undervalues the company are encouraged to contact KSF.
Exact Sciences Corporation (EXAS) Stock Analysis: Strong Revenue Growth Amid High Valuation
Exact Sciences Corporation (EXAS), a diagnostic company known for Cologuard and Oncotype DX tests, is experiencing strong revenue growth (20.10%) and high investor confidence, with its stock trading near its 52-week high. Despite a significant market capitalization of $19.38 billion, the company faces profitability challenges, evidenced by a negative EPS and return on equity. Its high forward P/E ratio of 91.34 indicates investors are betting on future growth, making it a high-risk, high-reward opportunity in the healthcare sector.
Assessing Exact Sciences (EXAS) Valuation After A Strong Momentum-Driven Share Price Run
Exact Sciences (EXAS) has seen strong momentum with a 71.29% share price return over 90 days and a 77.95% one-year total shareholder return. Despite this, the stock is considered 2% undervalued with a narrative fair value around $103.67, while analysts have a consensus price target of $63.143. Investors are urged to consider potential risks like R&D spending and competition impacting future growth.
Exact Sciences Stock Is Going Wild: Is This Cancer-Test Giant a Hidden Gem or Total Trap?
Exact Sciences Corporation (EXAS) is gaining significant attention for its cancer screening technology, particularly an at-home colon cancer test. The article examines whether the company is a promising growth opportunity or a risky investment, highlighting its legitimate product, real but not yet consistently profitable revenue, and significant stock price volatility. Investors are advised to consider their risk tolerance and long-term outlook before making a decision on this high-risk, high-potential bet in the healthcare sector.
Exact Sciences Corp.: Turning DNA Into a Weapon Against Cancer
Exact Sciences Corp. is revolutionizing cancer detection through non-invasive, DNA-driven tests like Cologuard and Oncotype. The company focuses on early cancer detection, challenging traditional methods by offering consumer-grade usability paired with rigorous genomics. Its strategy involves continuous innovation, expanding beyond current flagship products into multi-cancer early detection and minimal residual disease monitoring, aiming to solidify its market position against competitors.
Smart Oncology: 5 Stocks Chasing the $317B Prize
The precision oncology market is rapidly expanding, driven by advancements in biomarker-guided therapies and AI. This article highlights five key players—Oncolytics Biotech Inc., Exact Sciences Corp., Veracyte, Inc., Hologic, Inc., and Personalis, Inc.—that are at the forefront of this $317 billion industry. These companies are developing innovative solutions for cancer diagnosis and treatment, offering new hope for personalized and effective care.
Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Cancer Playbook
Exact Sciences Corp. is transforming cancer screening into a software-driven diagnostics platform, making early detection more routine. The company is known for its Cologuard at-home colon cancer screening test and has expanded into multi-cancer early detection and precision oncology. Their strategy focuses on noninvasive screening, precision oncology tools like Oncotype DX, and developing multi-cancer early detection (MCED) via a data-driven approach, positioning them as a critical infrastructure in cancer care.
Exact Sciences accelerates executive bonuses and equity awards ahead of merger
Exact Sciences Corp. announced that its board has approved accelerated vesting and payment of annual bonuses and equity awards for executive officers. This decision is related to the company's pending merger with Abbott Laboratories and aims to address potential tax implications under Sections 280G and 4999 of the Internal Revenue Code. The move also outlines specific accelerated payments for key executives and details regarding annual bonuses, RSU, and PSU awards, along with clawback provisions.
Harbor Capital Advisors Inc. Sells 29,990 Shares of Exact Sciences Corporation $EXAS
Harbor Capital Advisors Inc. significantly reduced its stake in Exact Sciences Corporation by selling 29,990 shares, decreasing its holdings by 61.6% to 18,705 shares. This comes amidst mixed analyst ratings, with a current consensus of "Hold" and a price target of $85, despite Exact Sciences beating Q3 earnings and revenue estimates. Insider selling has also been reported, with executives and directors offloading shares.
Exact Sciences Corporation (NASDAQ:EXAS) Given Average Recommendation of "Hold" by Analysts
Exact Sciences Corporation (NASDAQ:EXAS) has received a consensus "Hold" rating from analysts, with an average 1-year price target of $85.00, despite some recent downgrades and upgrades. The company exceeded quarterly earnings and revenue estimates but remains unprofitable with a negative net margin. Shares are trading near their 52-week high, with significant institutional ownership and recent insider share sales.
